Indian Pharmaceutical Market
- All
- News
- Videos
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
50+ Branded Semaglutide Generics To Enter India As Diabetes Drug Patent Expires In March 2026
Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely reducing treatment costs for diabetes and obesity patients.
-
Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment
AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation to sell and distribute Durvalumab solution for infusion used in cancer treatment.
-
India-US Trade Pact To Open $30 Trillion Market For Indian Exporters: Piyush Goyal
The India-US trade pact will open a $30 trillion market for Indian exporters, especially MSMEs, farmers and fishermen, Commerce and Industry Minister Piyush Goyal said.
-
India's Top Export Markets: A Shifting Landscape Explained In Graphics
The United States on Monday slashed tariffs on Indian goods to 18 per cent, down from the previously effective rate of 50 per cent.
-
US Revives Drug Origin Debate, Cites Indian Exports
US renewed a push to require country-of-origin labeling on prescription drugs, citing temporary restrictions on pharmaceutical exports during the Covid pandemic by India as evidence that America's drug supply remains vulnerable to foreign disruptions
-
India-EU Trade Pact Explained: $572 Billion Boost To Indian Pharma, MedTech Industry
The India-EU Free Trade Agreement opens access to the European Union's $572.3 billion pharmaceuticals and medical devices market, boosting India's pharma sector, employment, MSMEs and global supply chain integration, according to the government.
-
Indian Drugmakers Recall Medicines In The US Over Manufacturing Issues
Indian drugmakers Sun Pharmaceutical Industries and Cipla have recalled certain products from the US market due to manufacturing-related issues, according to the latest update from the US Food and Drug Administration (USFDA).
-
New Study Highlights Drug Pricing And Regulation Issues In India
A new government study exposes serious flaws in India's drug pricing and regulation infrastructure. This study reveals how systemic failures impact drug pricing.
-
Trump May Exclude Generic Drugs From Tariffs. Good News For India?
The Donald Trump administration has dropped plans to impose tariffs on generic drugs from foreign countries, following months of debate over whether to impose taxes on the majority of medications prescribed in the US.
-
Indian Pharma Giants Launch Low-Cost Generic Semaglutide Injections For Diabetes, Weight Management
New Delhi, March 21 (IANS) Three Indian pharmaceutical companies have launched generic versions of semaglutide injections, after the drug’s patent expired, offering lower‑cost options for patients managing Type 2 diabetes and obesity.
-
50+ Branded Semaglutide Generics To Enter India As Diabetes Drug Patent Expires In March 2026
Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely reducing treatment costs for diabetes and obesity patients.
-
Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment
AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation to sell and distribute Durvalumab solution for infusion used in cancer treatment.
-
India-US Trade Pact To Open $30 Trillion Market For Indian Exporters: Piyush Goyal
The India-US trade pact will open a $30 trillion market for Indian exporters, especially MSMEs, farmers and fishermen, Commerce and Industry Minister Piyush Goyal said.
-
India's Top Export Markets: A Shifting Landscape Explained In Graphics
The United States on Monday slashed tariffs on Indian goods to 18 per cent, down from the previously effective rate of 50 per cent.
-
US Revives Drug Origin Debate, Cites Indian Exports
US renewed a push to require country-of-origin labeling on prescription drugs, citing temporary restrictions on pharmaceutical exports during the Covid pandemic by India as evidence that America's drug supply remains vulnerable to foreign disruptions
-
India-EU Trade Pact Explained: $572 Billion Boost To Indian Pharma, MedTech Industry
The India-EU Free Trade Agreement opens access to the European Union's $572.3 billion pharmaceuticals and medical devices market, boosting India's pharma sector, employment, MSMEs and global supply chain integration, according to the government.
-
Indian Drugmakers Recall Medicines In The US Over Manufacturing Issues
Indian drugmakers Sun Pharmaceutical Industries and Cipla have recalled certain products from the US market due to manufacturing-related issues, according to the latest update from the US Food and Drug Administration (USFDA).
-
New Study Highlights Drug Pricing And Regulation Issues In India
A new government study exposes serious flaws in India's drug pricing and regulation infrastructure. This study reveals how systemic failures impact drug pricing.
-
Trump May Exclude Generic Drugs From Tariffs. Good News For India?
The Donald Trump administration has dropped plans to impose tariffs on generic drugs from foreign countries, following months of debate over whether to impose taxes on the majority of medications prescribed in the US.
